1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with cardiovascular agents in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirakawa, Y; Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A | 1 |
| Kass, DA; McKinsey, TA | 1 |
| Abman, SH; Chester, M; Grover, T; Tourneux, P | 1 |
| Gao, PJ; Jean-Charles, L; Wu, DJ; Wu, YJ; Xiao, B; Xu, JZ; Zhu, DL | 1 |
| Alvarez, SM; Browne, BM; Clelland, LJ; Miner, AS; Ratz, PH | 1 |
1 review(s) available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and cardiovascular agents
| Article | Year |
|---|---|
Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cardiomegaly; Cardiovascular Agents; Humans; Models, Biological; Molecular Structure; Pyridines; Receptors, Cell Surface; Signal Transduction | 2007 |
1 trial(s) available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and cardiovascular agents
| Article | Year |
|---|---|
Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylcholine; Aged; Cardiovascular Agents; Coronary Circulation; Coronary Vasospasm; Enzyme Inhibitors; Female; Heart Function Tests; Humans; Infusions, Intra-Arterial; Intracellular Signaling Peptides and Proteins; Microvascular Angina; Middle Aged; Myocardial Ischemia; Protein Serine-Threonine Kinases; rho-Associated Kinases; Treatment Outcome; Vasodilator Agents | 2003 |
3 other study(ies) available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and cardiovascular agents
| Article | Year |
|---|---|
Fasudil inhibits the myogenic response in the fetal pulmonary circulation.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Cardiovascular Agents; Constriction; Ductus Arteriosus; Female; Gestational Age; Pregnancy; Protein Kinase Inhibitors; Pulmonary Artery; Pulmonary Circulation; Regional Blood Flow; rho-Associated Kinases; Sheep; Time Factors; Vascular Resistance; Vasoconstriction; Vasodilation | 2008 |
Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apolipoproteins E; Atherosclerosis; Blood Pressure; Brachiocephalic Trunk; Cardiovascular Agents; Carotid Artery Diseases; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Immunohistochemistry; Lipids; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Acoustic; Protein Kinase Inhibitors; rho-Associated Kinases; Time Factors | 2009 |
Rho-kinase inhibition attenuates calcium-induced contraction in β-escin but not Triton X-100 permeabilized rabbit femoral artery.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Calcium; Cardiovascular Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Escin; Female; Femoral Artery; Indoles; Male; Maleimides; Mice; Muscle Contraction; Muscle, Smooth, Vascular; Octoxynol; Organ Culture Techniques; Permeability; Potassium Chloride; Rabbits; rho-Associated Kinases; Surface-Active Agents | 2011 |